Size, Share & Industry Analysis, By Type (Emulsion Adjuvants, Mineral Adjuvants, Other Adjuvants), By Application (Livestock Vaccines, Companion Animal Vaccines), and Regional Forecast, 2026-2034
Explore the report section by section.
The global veterinary vaccine adjuvants market was valued at USD 335.0 million in 2025 and is estimated at USD 356.4 million in 2026. The market is projected to reach USD 583.8 million by 2034, representing a 6.4% CAGR during 2026–2034.
Veterinary vaccine adjuvants are formulation components used to enhance or shape the immune response to vaccine antigens. Commercial selection is highly application-specific: the animal species, pathogen, antigen platform, desired duration of protection, route of administration, safety profile and production economics all influence which adjuvant system is appropriate. The market therefore spans mature mineral and emulsion technologies as well as newer polymeric, micro-emulsion, saponin and particulate approaches.
Animal-disease pressure provides a durable demand mechanism. WOAH's first State of the World's Animal Health report highlighted diseases reaching new areas and noted uneven access to livestock vaccines, while CDC estimates that more than six in ten known human infectious diseases can spread from animals. These public-health and food-security linkages support continued investment in veterinary vaccination, particularly where improved adjuvants can increase immune durability, broaden response or enable practical routes such as oral, nasal and in-ovo administration.
Supplier competition is increasingly influenced by formulation flexibility and supply security. Seppic's Montanide portfolio spans emulsion, micro-emulsion, polymer and oral-route technologies; Croda offers aluminium and other vaccine-adjuvant systems and expanded sustainably sourced squalene work across human and veterinary applications in 2025; SPI Pharma is broadening beyond alum through saponin-based adjuvants including VAC Saponin for veterinary use. The commercial opportunity therefore extends from traditional high-volume formulations to differentiated systems that improve safety, route flexibility and sourcing resilience.
Source: WOAH State of the World’s Animal Health; CDC One Health; EMA veterinary-adjuvant guideline.
The study covers adjuvant ingredients and formulation systems supplied for veterinary vaccines, including emulsion-based, mineral and other immune-enhancing technologies used in livestock and companion-animal vaccine development and commercial manufacturing.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million |
| By Type | Emulsion Adjuvants; Mineral Adjuvants; Others |
| By Application | Livestock Vaccines; Companion Animals Vaccines |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Key Market Players | SEPPIC; Croda International Plc; Vertellus; SPI Pharma; SDA BIO; Phibro Animal Health Corporation; Brenntag SE |
Market revenue includes veterinary-use vaccine adjuvant ingredients and formulated adjuvant systems sold to vaccine developers and manufacturers for incorporation into prophylactic animal vaccines. It includes mineral salts, oil or emulsion systems and other immune-enhancing technologies used specifically in veterinary formulations. It excludes the total value of finished veterinary vaccines, antigen manufacturing, diagnostics, therapeutics and adjuvant revenue attributable solely to human vaccines.
Where suppliers serve both human and veterinary markets, only the veterinary-use portion of adjuvant demand is included. Company-wide vaccine-adjuvant sales are not automatically treated as veterinary-market revenue unless the application split is known. The report focuses on commercial adjuvant value rather than the total economic value of animal vaccination programs.
WOAH reported that infectious animal diseases are affecting new areas and species, while African swine fever caused more than two million animal losses worldwide between January 2022 and February 2025. Disease expansion increases the economic value of prevention and supports new or reformulated vaccines for livestock and poultry. Adjuvant suppliers benefit when vaccine developers need stronger, longer-lasting or more targeted immune responses, particularly for inactivated or purified antigens that may be poorly immunogenic on their own.
CDC estimates that more than six in ten known infectious diseases in people can spread from animals and three in four new or emerging human infectious diseases originate in animals. This strengthens policy support for animal vaccination as a public-health tool, not only a farm-productivity input. For adjuvant suppliers, One Health priorities expand collaboration opportunities with public agencies, veterinary-biologics manufacturers and global disease-control programs.
EMA defines veterinary vaccine adjuvants as substances or compositions that potentiate or direct immune responses and requires quality, safety, environmental and efficacy data around adjuvant use. USDA APHIS similarly regulates veterinary biologics through the Center for Veterinary Biologics. These requirements lengthen qualification cycles and raise switching costs, favoring suppliers with documented manufacturing quality, formulation expertise and regulatory support.
The commercial objective is not simply to maximize immune response. Injection-site reactions, species-specific tolerability, residue concerns in food animals and route limitations can restrict otherwise potent adjuvants. Suppliers therefore compete on the balance between efficacy and safety, and newer polymer, micro-emulsion, saponin and particulate systems must demonstrate practical advantages over established mineral and emulsion technologies.
Squalene and Quillaja-derived saponins illustrate how raw-material sourcing can affect vaccine-development risk. Croda has expanded work on sustainably sourced squalene, while SPI Pharma and Q-VANT are commercializing biomass-derived saponin technologies. Reliable scalable supply is increasingly important because vaccine manufacturers want adjuvant platforms that can support commercial volumes without exposing programs to biodiversity, geographic or agricultural sourcing constraints.
Emulsion adjuvants account for approximately 58% of the supplied report model, reflecting long-standing use across livestock vaccines and the ability to tailor oil-in-water, water-in-oil and water-in-oil-in-water systems. Seppic's current Montanide ISA range illustrates this diversity. Growth is increasingly differentiated by application rather than a simple shift away from emulsions, with newer systems targeting safety, mucosal routes or specific immune profiles.
Seppic highlights veterinary adjuvant technologies for oral, nasal and in-ovo routes in addition to parenteral vaccination. These routes can improve practicality in poultry, aquaculture and large-population livestock settings by reducing individual injection requirements. Adjuvant suppliers that protect antigens through the gastrointestinal environment or support mucosal immunity can access higher-value formulation projects beyond conventional injectable vaccines.
SPI Pharma's partnership with Q-VANT has expanded access to biomass-derived saponins, including VAC Saponin for veterinary applications. Q-VANT describes its process as based on renewable Quillaja biomass, while SPI positions the platform around scalable supply and batch consistency. This development addresses a key bottleneck for saponin technologies: dependable raw-material access at commercial scale.
Croda reported that it launched cGMP-grade sustainably sourced squalene for customer use in 2025 and expanded active projects across human and veterinary applications. Squalene-based oil-in-water emulsions are important in modern adjuvant design, and alternative sourcing can reduce biodiversity concerns while improving supply-chain resilience. The market opportunity is therefore partly driven by reformulation of existing adjuvant chemistries with more sustainable feedstocks.
WOAH published practical guidelines for national procurement of veterinary vaccines and, in 2025, dedicated its Animal Health Forum to vaccine availability, access and demand. Better procurement discipline can increase the value of validated formulation inputs because vaccine manufacturers must meet clearer expectations around quality, efficacy and fit-for-purpose product characteristics. Adjuvant suppliers with regulatory documentation and robust manufacturing can benefit from this shift.
Veterinary adjuvant selection is driven by the immune response required, target species, antigen type, route and safety tolerance. No single chemistry is optimal across all veterinary vaccines, which supports a portfolio market rather than a winner-takes-all platform.
| Adjuvant Technology | Typical Role | Commercial Considerations |
|---|---|---|
| Oil / emulsion systems | Create depot effects and strong humoral or combined immune responses; widely used in livestock vaccine formulations. | Established performance and large commercial base, but formulation viscosity, reactogenicity and species-specific tolerability require careful optimization. |
| Aluminium / mineral adjuvants | Long-established immune enhancement with broad regulatory familiarity and manufacturing experience. | Cost-effective and well characterized; can remain preferred where a predominantly antibody-mediated response is adequate. |
| Polymeric / micro-emulsion systems | Enable lower-oil or water-based formulations and can improve safety while maintaining immune stimulation. | Supports differentiation where traditional emulsions cause unacceptable reactions or where route flexibility is needed. |
| Saponin-based systems | Enhance antigen presentation and cellular immunity and can support advanced formulations. | High biological potency and growing interest, but historic sourcing constraints increase the value of sustainable scalable production. |
| Oral / mucosal delivery technologies | Protect antigens and support immune stimulation at mucosal surfaces or through feed/water administration. | Potentially reduces handling cost for large animal populations and creates new value in poultry, aquaculture and mass-vaccination workflows. |
Supplier value increasingly includes formulation services and regulatory assistance. Seppic provides development, production and regulatory support around its Montanide range, while Croda and SPI Pharma position adjuvant portfolios alongside technical expertise. This service layer is important because changing an adjuvant can alter antigen adsorption, stability, immune kinetics, manufacturing process and regulatory documentation simultaneously.
The market is segmented into emulsion adjuvants, mineral adjuvants and other technologies. Emulsion adjuvants represent the leading product type, accounting for approximately 58% of 2025 market revenue in the supplied report model. The balance comprises mineral systems and newer polymeric, saponin, particulate and combination approaches.
Emulsion adjuvants hold approximately 58% of market revenue in the report model. Their scale reflects long-standing use in livestock vaccines, formulation versatility and the ability to generate durable immune responses. Through 2034 they are expected to remain the largest value segment, although growth is increasingly shaped by lower-reactogenicity formulations, sustainable oil sources and route-specific optimization.
Aluminium-based and related mineral systems remain important because they are well characterized, economical and familiar to regulators and manufacturers. Their growth is expected to be steadier than emerging technologies, with continued use where a strong humoral response and simple manufacturing process meet product requirements.
The 'others' category includes polymeric, micro-emulsion, saponin, particulate and combination systems. It is the principal innovation pool as developers seek mucosal immunity, reduced injection-site reactions, targeted innate pathways and more sustainable sourcing. Although smaller in current value, this category is expected to gain strategic importance in new vaccine platforms.
The report separates livestock vaccines and companion-animal vaccines. Livestock vaccines hold the leading share, accounting for approximately 60% of the supplied report model, because vaccination programs must protect large animal populations against diseases that affect production, trade, food security and farm economics.
Livestock vaccines account for approximately 60% of the report-model market. Demand is driven by cattle, swine, poultry, aquaculture and other production-animal disease-control programs, where adjuvants can improve duration of immunity or enable practical mass-vaccination strategies. Volume is large, but pricing is sensitive to farm economics and public procurement.
Companion-animal vaccines represent a smaller but higher-value opportunity in many developed markets. Veterinary clinics and pet owners place greater emphasis on safety, convenience and long-duration protection, creating room for differentiated adjuvants that reduce adverse reactions or support combination vaccines. Growth is linked to preventive-care penetration and premium veterinary spending.
The application mix affects formulation priorities. Livestock programs emphasize cost per dose, field durability and ease of administration at scale, while companion-animal products can support more premium formulations when safety and convenience improve owner or veterinarian acceptance.
North America is the largest regional market, accounting for more than 30% of 2025 revenue in the report model. The United States combines a large commercial animal-health industry with USDA Center for Veterinary Biologics regulation and strong companion-animal preventive care. The region is also an important development base for advanced adjuvant and vaccine technologies, supporting premium formulation demand.
Europe combines sophisticated veterinary-biologics regulation with strong animal-welfare and antimicrobial-reduction policies. EMA's specific guideline for adjuvants in veterinary vaccines requires detailed quality, safety and efficacy information, favoring well-documented suppliers. Livestock vaccination, companion-animal care and advanced formulation development sustain demand across major markets such as Germany, France, the United Kingdom and Italy.
Asia-Pacific is a major growth opportunity because of large livestock populations, intensive poultry and swine production, rising companion-animal ownership and recurring transboundary-disease risk. Government vaccination programs and export-oriented food production support volume, while local cost sensitivity increases the importance of scalable adjuvant manufacturing and practical mass-administration routes.
Latin American demand is closely tied to cattle, poultry and swine production in Brazil, Mexico, Argentina and other agricultural markets. Disease-control programs and export requirements can generate large vaccine volumes, favoring cost-effective emulsion and mineral systems. Growth opportunities also exist in companion-animal vaccination as urban veterinary services expand.
The region combines high disease burden with uneven vaccine access. WOAH has highlighted global gaps in vaccine availability, access and demand, issues that are particularly relevant in lower-resource livestock systems. Public procurement, donor-supported programs and improved cold-chain or mass-delivery technologies can expand adjuvant demand, but affordability and regulatory capacity remain important constraints.
Veterinary adjuvants sit within finished-vaccine regulatory frameworks rather than operating as unconstrained formulation excipients. The adjuvant's composition, safety and effect on efficacy can materially influence the data package required for a veterinary biologic.
| Authority / Framework | Relevant Requirement | Market Effect |
|---|---|---|
| EMA / CVMP | Requires quality, safety, environmental-risk and efficacy information for veterinary vaccine adjuvants; quantitative composition of immune-modulatory constituents should be stated in product information. | Favors suppliers with well-characterized materials, consistent manufacturing and regulatory documentation. |
| USDA APHIS Center for Veterinary Biologics | Regulates veterinary biologics in the United States and uses risk-analysis procedures for license applications and imports. | Creates a high compliance threshold for vaccine developers and supports demand for established, documented adjuvant components. |
| WOAH standards and procurement guidance | Promotes quality-assured veterinary vaccines, disease-specific standards and improved national procurement practices. | Encourages vaccine manufacturers to demonstrate fit-for-purpose quality and supports reliable adjuvant supply as part of product consistency. |
| Food-animal safety considerations | Adjuvant constituents, residues, local reactions and environmental effects may require specific assessment depending on species and product. | Limits some high-reactogenicity systems and increases the value of safer or lower-dose technologies. |
The regulatory environment increases supplier stickiness. Once an adjuvant is embedded in a licensed vaccine, changing chemistry or source can trigger comparability, stability, safety or efficacy work. Suppliers that maintain batch consistency, traceability and long-term manufacturing continuity can therefore retain business for the commercial life of a vaccine.
The veterinary vaccine adjuvants market is relatively concentrated around specialist excipient and adjuvant suppliers with established manufacturing quality and formulation expertise. The supplied report model indicates that the five largest manufacturers collectively account for a substantial majority of market revenue, with SEPPIC holding the leading position.
SEPPIC competes through a broad veterinary-focused portfolio spanning oil emulsions, micro-emulsions, polymers and oral-route technologies, supported by formulation, manufacturing and regulatory assistance. This breadth allows the supplier to address multiple species and vaccine platforms.
Croda combines established aluminium and vaccine-adjuvant capabilities with newer sustainable technologies. Its 2025 activity around cGMP-grade sustainably sourced squalene and veterinary projects illustrates how supply sustainability is becoming a differentiation factor.
SPI Pharma has expanded beyond traditional alum through partnerships that add saponin and advanced immune-stimulatory technologies. VAC Saponin provides a veterinary-specific offering based on renewable Quillaja biomass, broadening the company's position in next-generation adjuvants.
Other profiled suppliers compete through specialty chemistries, regional distribution, animal-health relationships and supply-chain reach. Their positioning is influenced by price, documentation, formulation support and the ability to serve both development-scale and commercial-scale requirements.
Competitive advantage is increasingly determined by three capabilities: a portfolio broad enough to solve species- and route-specific formulation problems; regulatory and technical support that shortens vaccine-development timelines; and reliable commercial-scale supply. New chemistry alone is insufficient if the supplier cannot provide reproducible GMP-grade material for the full product lifecycle.
17 January 2025: SEPPIC highlighted its expanded veterinary-adjuvant approach across parenteral, oral, nasal and in-ovo routes, positioning the Montanide portfolio around emulsion, micro-emulsion, polymer and oral-delivery technologies for animal vaccines.
23 May 2025: WOAH released its first State of the World's Animal Health report, reporting changing disease spread, uneven access to livestock vaccines and a 5% decline in antimicrobial use in animals between 2020 and 2022, strengthening the prevention and vaccination agenda.
29 May 2025: WOAH adopted an African swine fever vaccine standard after reporting more than two million ASF-related animal losses worldwide between January 2022 and February 2025, creating a clearer quality framework for future vaccine development.
25 January 2026: USDA APHIS updated its Center for Veterinary Biologics risk-analysis and summary-information guidance, reinforcing the structured regulatory review applied to veterinary biologics and imported products.
19 February 2026: WOAH published an ad hoc group report developing a standardized Target Product Profile template for veterinary vaccines, intended to align researchers, manufacturers, regulators, funders and end users around desired product attributes.
June 2026: Q-VANT Biosciences and SPI Pharma announced the commercial launch of QS-21 GH through their partnership, while SPI Pharma's current portfolio includes VAC Saponin specifically for veterinary applications, demonstrating the commercialization of scalable biomass-derived saponin technology.
The global veterinary vaccine adjuvants market is projected to grow from USD 356.4 million in 2026 to USD 583.8 million by 2034, at a 6.4% CAGR during 2026–2034. Growth is expected to remain anchored in livestock vaccination while higher-value innovation comes from route flexibility, safety optimization and sustainable next-generation adjuvant platforms.
| Forecast Variable | Observed Starting Point | Expected Effect Through 2034 |
|---|---|---|
| Disease pressure | WOAH reports expansion of transboundary diseases and >2M ASF-related animal losses from Jan 2022 to Feb 2025. | Sustains vaccine-development and reformulation activity across livestock species. |
| Emulsion leadership | Emulsion adjuvants represent ~58% of the report-model market. | Remain the largest value segment while shifting toward safer and more sustainable formulations. |
| Livestock vaccine demand | Livestock vaccines account for ~60% of the report-model application mix. | Supports volume growth, especially in poultry, swine, cattle and aquaculture disease-control programs. |
| Alternative routes | Commercial suppliers are developing oral, nasal, in-ovo and mucosal adjuvant technologies. | Creates above-market opportunities where mass vaccination can reduce handling cost and improve coverage. |
| Sustainable raw materials | Croda sustainable squalene and SPI/Q-VANT biomass-derived saponins are entering commercial portfolios. | Improves supply resilience and supports next-generation formulation differentiation. |
Emulsion adjuvants are expected to retain the largest market share, but the fastest value creation should occur in advanced systems that improve safety, route flexibility or supply security. North America is expected to remain the largest regional market, while Asia-Pacific should capture a growing share of incremental demand as livestock vaccination intensity and veterinary manufacturing capacity expand.
The study is structured to support strategy, market-entry assessment, product planning, competitive benchmarking and commercial opportunity analysis across the defined market.
Market estimates are developed through bottom-up and top-down triangulation. Bottom-up work evaluates the addressable supplier set, system or formulation portfolios, application exposure, geographic presence, installed or recurring demand, channel structure and replacement or replenishment patterns. Top-down work uses the relevant regulated activity base, procedure or production intensity, technology penetration, compliance requirements and regional adoption patterns to establish an independent market range.
Primary research is used to validate market structure, purchasing criteria, adoption barriers, product differentiation, pricing behavior and competitive positioning. Secondary research emphasizes regulators, government agencies, standards and professional bodies, peer-reviewed literature where relevant, company annual reports, investor disclosures and official product documentation. Market-research/report-selling websites are excluded from the evidence base.
Forecasts incorporate veterinary vaccine production, livestock and companion-animal vaccination intensity, disease-control programs, adjuvant penetration by vaccine platform, technology substitution, regulatory qualification timelines, raw-material supply, pricing, route-of-administration trends and regional animal-health investment. Segment shares are reconciled across type, application and geography without allocating the total sales of multi-application human-and-veterinary adjuvant suppliers to the veterinary market.
The market was valued at USD 335.0 million in 2025 and is estimated at USD 356.4 million in 2026. It is projected to reach USD 583.8 million by 2034, representing a 6.4% CAGR during 2026–2034.
Emulsion adjuvants lead the market, accounting for approximately 58% of 2025 revenue in the supplied report model, supported by long-standing use in livestock vaccines and broad formulation flexibility.
Livestock vaccines hold the largest application share at approximately 60% in the supplied report model because large animal populations require recurring disease-prevention programs across cattle, swine, poultry and other production species.
North America is the largest regional market, accounting for more than 30% of 2025 revenue in the report model, supported by advanced veterinary-biologics regulation, strong animal-health R&D and high preventive-care adoption.
Major drivers include transboundary and zoonotic disease risk, livestock productivity and food-security needs, companion-animal preventive care, development of new vaccine platforms and demand for adjuvants that improve immune durability or enable new administration routes.
Key trends include safer emulsion systems, polymeric and micro-emulsion formulations, sustainable saponins, sustainably sourced squalene, and oral, nasal, mucosal or in-ovo technologies that can improve mass-vaccination practicality.
The report profiles SEPPIC, Croda International, Vertellus, SPI Pharma, SDA BIO, Phibro Animal Health Corporation and Brenntag SE.
Adjuvants are evaluated as part of finished veterinary vaccines. EMA requires quality, safety, environmental and efficacy information, while USDA APHIS regulates veterinary biologics in the United States through the Center for Veterinary Biologics.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.